RITONAVIRI COMPRESSI RITONAVIR TABLETS. Final text for addition to The International Pharmacopoeia (July 2012)

Size: px
Start display at page:

Download "RITONAVIRI COMPRESSI RITONAVIR TABLETS. Final text for addition to The International Pharmacopoeia (July 2012)"

Transcription

1 July 2012 RITONAVIRI COMPRESSI RITONAVIR TABLETS Final text for addition to The International Pharmacopoeia (July 2012) This monograph was adopted at the Forty-sixth WHO Expert Committee on Specifications for Pharmaceutical Preparations in October 2011 for addition to the 4 th Edition of the International Pharmacopoeia Category. Antiretroviral (Protease Inhibitor). Storage. Ritonavir tablets should be stored in a tightly closed container, at temperatures not exceeding 30 C. Additional information. Strength in the current WHO Model list of essential medicines: 25 mg, 100 mg. Requirements Comply with the monograph for Tablets. Definition. Ritonavir tablets contain not less than 90.0% and not more than 110.0% of the amount of ritonavir (C 37 H 48 N 6 O 5 S 2 ) stated on the label. Manufacture. Ritonavir tablets are manufactured using Ritonavir in the amorphous form in order to ensure suitable solubility properties. Identity tests A. Carry out test A.1 or, where UV detection is not available, test A.2. A.1 Carry out the test as described under Thin-layer chromatography, using silica gel R6 as the coating substance and a mixture of 67 volumes of dichloromethane R, 20 volumes of acetonitrile R, 10 volumes of methanol R

2 page 2 and 3 volumes of ammonia (~260 g/l) TS as the mobile phase. Apply separately to the plate 10 µl of each of the following two solutions in methanol R. For solution (A) shake a quantity of the powdered tablets containing 25 mg of Ritonavir with 5 ml and filter. Add 0.5 ml of ammonia (~260 g/l) TS to 2 ml of the filtrate and shake. For solution (B) use 2 ml of a 5 mg/ml solution of ritonavir RS. Add 0.5 ml of ammonia (~260 g/l) TS and shake. After removing the plate from the chromatographic chamber, allow it to dry exhaustively in a current of cool air. Examine the chromatogram in ultraviolet light (254 nm). The principal spot obtained with solution A corresponds in position, appearance and intensity with that obtained with solution B. A.2 Carry out the test as described under Thin-layer chromatography, using the conditions described above under test A.1 but using silica gel R5 as the coating substance. Spray lightly with basic potassium permanganate (5 g/l) TS and examine the chromatogram in daylight. The principal spot obtained with solution A corresponds in position, appearance, and intensity with that obtained with solution B. B. See the test described under Assay. The retention time of the principal peak in the chromatogram obtained with solution (1) is similar to that in the chromatogram obtained with solution (2). Dissolution. Carry out the test as described under 5.5 Dissolution test for solid oral dosage forms, using as the dissolution medium, 900 ml of hydrochloric acid (0.1 mol/l) VS, and rotating the paddle at 75 revolutions per minute. At 90 minutes withdraw a sample of 10 ml of the medium through an in-line filter. Allow the filtered sample to cool down to room temperature. Determine the content of ritonavir (C 37 H 48 N 6 O 5 S 2 ) in the medium by Highperformance liquid chromatography, using the conditions described under Assay and a suitable solution of ritonavir RS as a reference solution. For each of the six tablets tested, calculate the total amount of ritonavir (C 37 H 48 N 6 O 5 S 2 ) in the medium. The amount in solution for each tablet is not less than 80% of the amount stated

3 page 3 on the label. If the amount obtained for one of the six tablets is less than 80%, repeat the test using a further six tablets; the average amount for all 12 tablets tested is not less than 75% and no tablet releases less than 60%. Related substances Carry out the test as described under High-performance liquid chromatography, using the conditions described under Assay. Prepare the following solutions using a mixture of 70 volumes of mobile phase A and 30 volumes of mobile phase B as diluent. For solution (1) shake a quantity of the powdered tablets containing 25 mg of Ritonavir with 50 ml of diluent, filter and use the clear filtrate. For solution (2) dilute a suitable volume of solution (1) to obtain a concentration of 0.5 µg of Ritonavir per ml. For the system suitability test: prepare solution (3) using 5 ml of solution (1) and 1 ml of sulfuric acid (475 g/l) TS, heat in a boiling water bath for 20 minutes. Operate with a flow rate of 1.0 ml per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 240 nm. Maintain the column temperature at 35 C. Inject 20 µl of solution (3). The test is not valid unless the resolution between the principal peak (retention time about 22 minutes) and the peak with a relative retention of about 0.8 is at least 2.0. The test is also not valid unless the resolution between the principal peak and the peak with a relative retention of about 1.5 is at least 6.5. If necessary adjust the amount of acetonitrile in both mobile phases A and B, or adjust the gradient programme. Inject separately 20 µl each of solutions (1) and (2). In the chromatogram obtained with solution (1), the area of any peak, other than the principal peak, is not greater than three times the area of the principal peak in the chromatogram obtained with solution (2) (0.3%); the area of not more than two such peaks is greater than twice the area of the principal peak in the chromatogram obtained with solution (2) (0.2%); the area of not more than four such peaks is greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.1%). The sum of the areas of all peaks, other than the principal peak, is not greater than ten times the area of the principal peak in the

4 page 4 chromatogram obtained with solution (2) (1.0%). Disregard any peak with an area less than 0.5 times the area of the principal peak in the chromatogram obtained with solution (2) (0.05%). Disregard any peak with a retention time less than the retention time of the peak obtained with solution (3) with a relative retention of about 0.5. Assay Carry out the test as described under High-performance liquid chromatography, using a stainless steel column (25 cm x 4.6 mm) packed with base-deactivated particles of silica gel the surface of which has been modified with chemically bonded octadecylsilyl groups (5 µm). 1 Use the following conditions for gradient elution: Mobile phase A: 35 volumes of acetonitrile R, 28 volumes of sodium phosphate buffer ph 4.0 and 37 volumes of water R. Mobile phase B: 70 volumes of acetonitrile R, 28 volumes of sodium phosphate buffer ph 4.0 and 2 volumes of water R. Prepare the sodium phosphate buffer ph 4.0 by dissolving 7.8 g of sodium dihydrogen phosphate dihydrate R and 1.88 g of sodium hexanesulfonate R in 800 ml of water R, adjust the ph to 4.0 by adding phosphoric acid (~105 g/l) TS and dilute to 1000 ml with water R. Time Mobile phase A Mobile phase B Comments (min) (% v/v) (% v/v) Isocratic to 0 30 to 100 Linear gradient Isocratic to to 30 Linear gradient Isocratic re-equilibration 1 Hypersil BDS C18 has been found suitable.

5 page 5 Prepare the following solutions using a mixture of 70 volumes of mobile phase A and 30 volumes of mobile phase B as diluent. For solution (1) weigh and powder 20 tablets. Shake a quantity of the powdered tablets containing 25 mg of Ritonavir with 50 ml of diluent, filter and use the clear filtrate. For solution (2) use 0.5 mg of ritonavir RS per ml of diluent. Operate with a flow rate of 1.0 ml per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 240 nm. Maintain the column temperature at 35 C. For the system suitability test: prepare solution (3) using 5 ml of solution (1) and 1 ml of sulfuric acid (475 g/l) TS, heat in a boiling water bath for 20 minutes. Inject 20 µl of solution (3). The test is not valid unless the resolution between the principal peak (retention time about 22 minutes) and the peak with a relative retention of about 0.8 is at least 2.0. The test is also not valid unless the resolution between the principal peak and the peak with a relative retention of about 1.5 is at least 6.5. Inject separately 20 µl each of solutions (1) and (2). Measure the areas of the peak responses obtained in the chromatograms from solutions (1) and (2), and calculate the content of ritonavir (C 37 H 48 N 6 O 5 S 2 ) in the tablets. ***

TENOFOVIR TABLETS: Final text for addition to The International Pharmacopoeia (June 2010)

TENOFOVIR TABLETS: Final text for addition to The International Pharmacopoeia (June 2010) June 2010 TENOFOVIR TABLETS: Final text for addition to The International Pharmacopoeia (June 2010) This monograph was adopted at the Forty-fourth WHO Expert Committee on Specifications for Pharmaceutical

More information

ARTESUNATE TABLETS: Final text for revision of The International Pharmacopoeia (December 2009) ARTESUNATI COMPRESSI ARTESUNATE TABLETS

ARTESUNATE TABLETS: Final text for revision of The International Pharmacopoeia (December 2009) ARTESUNATI COMPRESSI ARTESUNATE TABLETS December 2009 ARTESUNATE TABLETS: Final text for revision of The International Pharmacopoeia (December 2009) This monograph was adopted at the Forty-fourth WHO Expert Committee on Specifications for Pharmaceutical

More information

EMTRICITABINE AND TENOFOVIR TABLETS

EMTRICITABINE AND TENOFOVIR TABLETS September 2010 RESTRICTED EMTRICITABINE AND TENOFOVIR TABLETS Draft proposal for The International Pharmacopoeia (September2010) REVISED DRAFT FOR COMMENT This document was provided by a quality control

More information

DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA EFAVIRENZ, EMTRICITABINE AND TENOFOVIR TABLETS

DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA EFAVIRENZ, EMTRICITABINE AND TENOFOVIR TABLETS September 2010 RESTRICTED DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA EFAVIRENZ, EMTRICITABINE AND TENOFOVIR TABLETS (August 2010) DRAFT FOR COMMENT This document was provided by a quality control

More information

CYCLOSERINI CAPSULAE - CYCLOSERINE CAPSULES (AUGUST 2015)

CYCLOSERINI CAPSULAE - CYCLOSERINE CAPSULES (AUGUST 2015) August 2015 Document for comment 1 2 3 4 5 CYCLOSERINI CAPSULAE - CYCLOSERINE CAPSULES DRAFT PROPOSAL FOR THE INTERNATIONAL PHARMACOPOEIA (AUGUST 2015) DRAFT FOR COMMENT 6 Should you have any comments

More information

INTERNATIONAL PHARMACOPOEIA MONOGRAPH ON LAMIVUDINE TABLETS

INTERNATIONAL PHARMACOPOEIA MONOGRAPH ON LAMIVUDINE TABLETS RESTRICTED INTERNATIONAL PHARMACOPOEIA MONOGRAPH ON LAMIVUDINE TABLETS DRAFT FOR COMMENT Please address any comments you may have on this document, by 12 July 2006, to Dr S. Kopp, Quality Assurance and

More information

Tenofovir disoproxil fumarate (Tenofoviri disoproxili fumaras)

Tenofovir disoproxil fumarate (Tenofoviri disoproxili fumaras) C 19 H 30 N 5 O 10 P. C 4 H 4 O 4 Relative molecular mass. 635.5. Chemical names. bis(1-methylethyl) 5-{[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl}-5-oxo-2,4,6,8-tetraoxa-5-λ 5 - phosphanonanedioate

More information

LEVONORGESTREL AND ETHINYLESTRADIOL TABLETS. (January 2012) DRAFT FOR COMMENT

LEVONORGESTREL AND ETHINYLESTRADIOL TABLETS. (January 2012) DRAFT FOR COMMENT January 2012 RESTRICTED DRAFT PROPOSAL FOR The International Pharmacopoeia LEVONORGESTREL AND ETHINYLESTRADIOL TABLETS (January 2012) DRAFT FOR COMMENT This document was provided by a quality control expert.

More information

SULFAMETHOXAZOLE AND TRIMETHOPRIM TABLETS Draft proposal for The International Pharmacopoeia (September 2010)

SULFAMETHOXAZOLE AND TRIMETHOPRIM TABLETS Draft proposal for The International Pharmacopoeia (September 2010) September 2010 RESTRICTED SULFAMETHOXAZOLE AND TRIMETHOPRIM TABLETS Draft proposal for The International Pharmacopoeia (September 2010) REVISED DRAFT FOR COMMENT This document was provided by a quality

More information

ARTENIMOLUM ARTENIMOL. Adopted revised text for addition to The International Pharmacopoeia

ARTENIMOLUM ARTENIMOL. Adopted revised text for addition to The International Pharmacopoeia February 2012 ARTENIMOLUM ARTENIMOL Adopted revised text for addition to The International Pharmacopoeia This monograph was adopted at the Forty-sixth WHO Expert Committee on Specifications for Pharmaceutical

More information

DRAFT PROPOSAL FOR THE INTERNATIONAL PHARMACOPOEIA: CARBAMAZEPINI COMPRESSI - CARBAMAZEPINE TABLETS

DRAFT PROPOSAL FOR THE INTERNATIONAL PHARMACOPOEIA: CARBAMAZEPINI COMPRESSI - CARBAMAZEPINE TABLETS December 2015 Draft document for comment 1 2 3 4 5 6 DRAFT PROPOSAL FOR THE INTERNATIONAL PHARMACOPOEIA: CARBAMAZEPINI COMPRESSI - CARBAMAZEPINE TABLETS (December 2015) REVISED DRAFT FOR COMMENT Should

More information

PROPOSAL FOR REVISION OF MONOGRAPH PUBLISHED IN The International Pharmacopoeia: REVISION OF ph test ABACAVIR ORAL SOLUTION (JULY 2012)

PROPOSAL FOR REVISION OF MONOGRAPH PUBLISHED IN The International Pharmacopoeia: REVISION OF ph test ABACAVIR ORAL SOLUTION (JULY 2012) July 2012 RESTRICTED PROPOSAL FOR REVISION OF MONOGRAPH PUBLISHED IN The International Pharmacopoeia: REVISION OF ph test ABACAVIR ORAL SOLUTION (JULY 2012) PROPOSED REVISION FOR COMMENT The background

More information

ZIDOVUDINE, LAMIVUDINE AND ABACAVIR TABLETS Draft proposal for The International Pharmacopoeia (September 2006)

ZIDOVUDINE, LAMIVUDINE AND ABACAVIR TABLETS Draft proposal for The International Pharmacopoeia (September 2006) September 2006 RESTRICTED ZIDOVUDINE, LAMIVUDINE AND ABACAVIR TABLETS Draft proposal for The International Pharmacopoeia (September 2006) This document was provided by a contracted quality control laboratory.

More information

TENOFOVIRI DISOPROXILIS FUMARAS TENOFOVIR DISOPROXIL FUMARATE

TENOFOVIRI DISOPROXILIS FUMARAS TENOFOVIR DISOPROXIL FUMARATE August 2009 RESTRICTED TENOFOVIRI DISOPROXILIS FUMARAS TENOFOVIR DISOPROXIL FUMARATE DRAFT PROPOSAL FOR THE INTERNATIONAL PHARMACOPOEIA FOR COMMENT Please send any comments on this document to Dr S. Kopp

More information

CYCLOSERINE Proposal for revision of The International Pharmacopoeia (August 2012)

CYCLOSERINE Proposal for revision of The International Pharmacopoeia (August 2012) August 2012 RESTRICTED CYCLOSERINE Proposal for revision of The International Pharmacopoeia (August 2012) Draft for comment This document was provided by a quality control expert. Should you have any comments

More information

ABACAVIR SULFATE Proposal for revision of The International Pharmacopoeia (August 2012)

ABACAVIR SULFATE Proposal for revision of The International Pharmacopoeia (August 2012) August 2012 RESTRICTED ABACAVIR SULFATE Proposal for revision of The International Pharmacopoeia (August 2012) Draft for comment This document was provided by a quality control expert. Should you have

More information

The International Pharmacopoeia TENOFOVIR DISOPROXIL FUMARATE (JULY 2012)

The International Pharmacopoeia TENOFOVIR DISOPROXIL FUMARATE (JULY 2012) July 2012 RESTRICTED PROPOSAL FOR REVISION OF MONOGRAPH PUBLISHED IN THE FOURTH EDITION OF The International Pharmacopoeia TENOFOVIR DISOPROXIL FUMARATE (JULY 2012) PROPOSED REVISION FOR COMMENT This document

More information

Draft monograph for inclusion in. The International Pharmacopoeia. Dextromethorphani solutionum peroralum - Dextromethorphan oral solution

Draft monograph for inclusion in. The International Pharmacopoeia. Dextromethorphani solutionum peroralum - Dextromethorphan oral solution August 2015 Draft document for comment 1 2 3 4 5 6 Draft monograph for inclusion in The International Pharmacopoeia Dextromethorphani solutionum peroralum - Dextromethorphan oral solution (August 2015)

More information

CLINDAMYCIN PALMITATE

CLINDAMYCIN PALMITATE February 2018 Document for comment 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 CLINDAMYCIN PALMITATE POWDER FOR ORAL

More information

CLINDAMYCIN PHOSPHATE (CLINDAMYCINI PHOSPHAS) REVISED DRAFT MONOGRAPH FOR INCLUSION IN The International Pharmacopoeia (August 2016)

CLINDAMYCIN PHOSPHATE (CLINDAMYCINI PHOSPHAS) REVISED DRAFT MONOGRAPH FOR INCLUSION IN The International Pharmacopoeia (August 2016) August 2016 Draft for comments 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 CLINDAMYCIN PHOSPHATE (CLINDAMYCINI PHOSPHAS)

More information

Draft proposal for The International Pharmacopoeia

Draft proposal for The International Pharmacopoeia April 2012 RESTRICTED SULFAMETHOXAZOLE AND TRIMETHOPRIM INTRAVENOUS INFUSION Draft proposal for The International Pharmacopoeia (April 2012) DRAFT FOR COMMENT This document was provided by a quality control

More information

DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA PAEDIATRIC RETINOL ORAL SOLUTION (August 2010)

DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA PAEDIATRIC RETINOL ORAL SOLUTION (August 2010) August 2010 RESTRICTED DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA PAEDIATRIC RETINOL ORAL SOLUTION (August 2010) DRAFT FOR COMMENT This document was provided by a quality control expert and was

More information

PROPOSAL FOR REVISION OF MONOGRAPH IN THE FOURTH EDITION OF The International Pharmacopoeia MEFLOQUINE HYDROCHLORIDE (JANUARY 2012) DRAFT FOR COMMENT

PROPOSAL FOR REVISION OF MONOGRAPH IN THE FOURTH EDITION OF The International Pharmacopoeia MEFLOQUINE HYDROCHLORIDE (JANUARY 2012) DRAFT FOR COMMENT January 2012 RESTRICTED PROPOSAL FOR REVISION OF MONOGRAPH IN THE FOURTH EDITION OF The International Pharmacopoeia MEFLOQUINE HYDROCHLORIDE (JANUARY 2012) DRAFT FOR COMMENT This document was provided

More information

Final text for addition to The International Pharmacopoeia (June 2010)

Final text for addition to The International Pharmacopoeia (June 2010) June 2010 KANAMYCIN ACID SULFATE: Final text for addition to The International Pharmacopoeia (June 2010) This monograph was adopted at the Forty-fourth WH Expert Committee on Specifications for Pharmaceutical

More information

PROPOSAL FOR REVISION OF MONOGRAPH PUBLISHED IN THE FOURTH EDITION OF The International Pharmacopoeia

PROPOSAL FOR REVISION OF MONOGRAPH PUBLISHED IN THE FOURTH EDITION OF The International Pharmacopoeia August 2011 RESTRICTED PRPSAL FR REVISIN F MNGRAP PUBLISED IN TE FURT EDITIN F The International Pharmacopoeia ARTESUNATE (August 2011) PRPSED REVISIN FR CMMENT Should you have any comments on the attached

More information

REVISED DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA RETINOL CONCENTRATE, OILY FORM. (August 2010)

REVISED DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA RETINOL CONCENTRATE, OILY FORM. (August 2010) August 2010 RESTRICTED REVISED DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA RETINOL CONCENTRATE, OILY FORM (August 2010) DRAFT FOR COMMENT This document was provided by a quality control expert

More information

Quetiapine Tablets. Expert Committee Monographs Chemical Medicines 4 Reason for Revision Compliance

Quetiapine Tablets. Expert Committee Monographs Chemical Medicines 4 Reason for Revision Compliance Quetiapine Tablets Type of Posting Revision Bulletin Posting Date 25 Sep 2015 Official Date 01 Nov 2015 Expert Committee Monographs Chemical Medicines 4 Reason for Revision Compliance In accordance with

More information

The Nitrofurantoin Capsules Revision Bulletin supersedes the currently official monograph.

The Nitrofurantoin Capsules Revision Bulletin supersedes the currently official monograph. Nitrofurantoin Capsules Type of Posting Revision Bulletin Posting Date 28 Dec 2018 Official Date 01 Jan 2019 Expert Committee Chemical Medicines Monographs 1 Reason for Revision Compliance In accordance

More information

Methotrexate. (Ph. Eur. monograph 0560) C 20 H 22 N 8 O Action and use. Dihydrofolate reductase inhibitor; cytostatic.

Methotrexate. (Ph. Eur. monograph 0560) C 20 H 22 N 8 O Action and use. Dihydrofolate reductase inhibitor; cytostatic. Browse: British Pharmacopoeia 2013 British Pharmacopoeia Volume I & II Monographs: Medicinal and Pharmaceutical Substances Methotrexate Methotrexate General Notices (Ph. Eur. monograph 0560) C 20 H 22

More information

Telmisartan and Hydrochlorothiazide Tablets. Type of Posting. Revision Bulletin Posting Date. 26 Jan 2018 Official Date

Telmisartan and Hydrochlorothiazide Tablets. Type of Posting. Revision Bulletin Posting Date. 26 Jan 2018 Official Date Telmisartan and Hydrochlorothiazide Tablets Type of Posting Revision Bulletin Posting Date 26 Jan 2018 Official Date 01 Feb 2018 Expert Committee Chemical Medicines Monographs 2 Reason for Revision Compliance

More information

Rebaudioside a From Multiple Gene Donors Expressed in Yarrowia Lipolytica

Rebaudioside a From Multiple Gene Donors Expressed in Yarrowia Lipolytica Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 82 nd meeting 2016 Rebaudioside a From Multiple Gene Donors Expressed in Yarrowia Lipolytica This

More information

Heparin Sodium ヘパリンナトリウム

Heparin Sodium ヘパリンナトリウム Heparin Sodium ヘパリンナトリウム Add the following next to Description: Identification Dissolve 1 mg each of Heparin Sodium and Heparin Sodium Reference Standard for physicochemical test in 1 ml of water, and

More information

This revision also necessitates a change in the table numbering in the test for Organic Impurities.

This revision also necessitates a change in the table numbering in the test for Organic Impurities. Methylphenidate Hydrochloride Extended-Release Tablets Type of Posting Notice of Intent to Revise Posting Date 27 Jul 2018 Targeted Official Date To Be Determined, Revision Bulletin Expert Committee Chemical

More information

Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 82 nd meeting 2016.

Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 82 nd meeting 2016. Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 82 nd meeting 2016 Aspartame This monograph was also published in: Compendium of Food Additive

More information

contents of the currently official monograph. Please refer to the current edition of the USP NF for official text.

contents of the currently official monograph. Please refer to the current edition of the USP NF for official text. Diltiazem Hydrochloride Extended-Release Capsules Type of Posting Notice of Intent to Revise Posting Date 25 May 2018 Targeted Official Date To Be Determined, Revision Bulletin Expert Committee Chemical

More information

Compliance. Should you have any questions, please contact Behnaz Almasi, Associate Scientific Liaison ( or

Compliance. Should you have any questions, please contact Behnaz Almasi, Associate Scientific Liaison ( or Extended-Release Tablets Type of Posting Revision Bulletin Posting Date 30 Mar 2018 Official Date 01 Apr 2018 Expert Committee Chemical Medicines Monographs 3 Reason for Revision Compliance In accordance

More information

Tramadol Hydrochloride Extended-Release Tablets. Expert Committee Chemical Medicines Monographs 2 Reason for Revision Compliance

Tramadol Hydrochloride Extended-Release Tablets. Expert Committee Chemical Medicines Monographs 2 Reason for Revision Compliance Tramadol Hydrochloride Extended-Release Tablets Type of Posting Revision Bulletin Posting Date 27 May 2016 Official Date 01 Jun 2016 Expert Committee Chemical Medicines Monographs 2 Reason for Revision

More information

Thank you for your requests under the Freedom of Information Act Please find below responses to your questions.

Thank you for your requests under the Freedom of Information Act Please find below responses to your questions. Our reference: FOI/12-332 Dear Ms Mallinson Thank you for your requests under the Freedom of Information Act 2000. Please find below responses to your questions. 1. Please e-mail copies of the minutes

More information

Revision of monograph in the 4 th Edition of The International Pharmacopoeia (August 2008)

Revision of monograph in the 4 th Edition of The International Pharmacopoeia (August 2008) August 2008 RESTRICTED MEBENDAZOLE Revision of monograph in the 4 th Edition of The International Pharmacopoeia (August 2008) REVISED DRAFT FOR ADOPTION This document was provided by a quality control

More information

Revision Bulletin 23 Feb Mar 2018 Chemical Medicines Monographs 3 Compliance

Revision Bulletin 23 Feb Mar 2018 Chemical Medicines Monographs 3 Compliance Esomeprazole Magnesium Delayed-Release Capsules Type of Posting Posting Date Official Date Expert Committee Reason for Revision Revision Bulletin 23 Feb 2018 01 Mar 2018 Chemical Medicines Monographs 3

More information

Title Revision n date

Title Revision n date A. THIN LAYER CHROMATOGRAPHIC TECHNIQUE (TLC) 1. SCOPE The method describes the identification of hydrocortisone acetate, dexamethasone, betamethasone, betamethasone 17-valerate and triamcinolone acetonide

More information

Revision Bulletin 28 Jul Aug 2017 Chemical Medicines Monographs 3

Revision Bulletin 28 Jul Aug 2017 Chemical Medicines Monographs 3 Oxybutynin Chloride Extended-Release Tablets Type of Posting Posting Date Official Date Expert Committee Reason for Revision Revision Bulletin 28 Jul 2017 01 Aug 2017 Chemical Medicines Monographs 3 Compliance

More information

contents of the monograph in effect today. Please refer to the current edition of the USP NF for official text.

contents of the monograph in effect today. Please refer to the current edition of the USP NF for official text. Metoprolol Succinate Extended-Release Tablets Type of Posting Notice of Intent to Revise Posting Date 26 Jan 2018, revised 12 Feb 2018 1 Targeted Official Date To Be Determined, Revision Bulletin Expert

More information

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR ESTIMATION OF LACOSAMIDE IN BULK AND ITS PHARMACEUTICAL FORMULATION

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR ESTIMATION OF LACOSAMIDE IN BULK AND ITS PHARMACEUTICAL FORMULATION http://www.rasayanjournal.com Vol.4, No.3 (2011), 666-672 ISSN: 0974-1496 CODEN: RJCABP DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR IN BULK AND ITS PHARMACEUTICAL FORMULATION V.Kalyan Chakravarthy*

More information

Pharmacopeial Forum 818 INTERIM REVISION ANNOUNCEMENT Vol. 35(4) [July Aug. 2009] ERRATA

Pharmacopeial Forum 818 INTERIM REVISION ANNOUNCEMENT Vol. 35(4) [July Aug. 2009] ERRATA 818 INTERIM REVISION ANNOUNCEMENT Vol. 35(4) [July Aug. 2009] ERRATA Following is a list of errata and corrections to USP NF. The page number indicates where the item is found and in which official or

More information

IJPAR Vol.3 Issue 4 Oct-Dec-2014 Journal Home page:

IJPAR Vol.3 Issue 4 Oct-Dec-2014 Journal Home page: IJPAR Vol.3 Issue 4 Oct-Dec-2014 Journal Home page: ISSN: 2320-2831 Research article Open Access Method development and validation of tenofovir disoproxil fumerate and emtricitabine in combined tablet

More information

SIMAROUBA CEDRON FOR HOMOEOPATHIC PREPARATIONS CEDRON FOR HOMOEOPATHIC PREPARATIONS

SIMAROUBA CEDRON FOR HOMOEOPATHIC PREPARATIONS CEDRON FOR HOMOEOPATHIC PREPARATIONS SIMAROUBA CEDRON FOR HOMOEOPATHIC PREPARATIONS CEDRON FOR HOMOEOPATHIC PREPARATIONS Simaba cedron ad praeparationes homoeopathicas Other Latin name used in homoeopathy: Simaruba DEFINITION Dried cotyledons

More information

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD ESTIMATION OF TOLVAPTAN IN BULK PHARMACEUTICAL FORMULATION

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD ESTIMATION OF TOLVAPTAN IN BULK PHARMACEUTICAL FORMULATION http://www.rasayanjournal.com Vol.4, No.1 (2011), 165-171 ISSN: 0974-1496 CODEN: RJCABP DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR AND ITS PHARMACEUTICAL FORMULATION V. Kalyana Chakravarthy * and

More information

ANALYTICAL TECHNIQUES FOR THE QUALITY OF ANTI- AIDS DRUGS

ANALYTICAL TECHNIQUES FOR THE QUALITY OF ANTI- AIDS DRUGS Research Article N. Bala Krishna, IJPRBS, 2013; Volume 2(1): 63-77 ISSN: 2277-8713 IJPRBS N.BALAA KRISHNA, Dr. M.V.V NAGESWARA REDDY IJPRBS-QR CODE PAPER-QR CODE DEVELOPMENT OF NEW ANALYTICAL TECHNIQUES

More information

Flupyradifurone. HPLC Method

Flupyradifurone. HPLC Method HPLC Method CIPAC Collaboration Trial according to CIPAC Information Sheet No 308 by Alexandra Michel Crop Science Division Bayer Aktiengesellschaft Alfred-Nobel-Str. 50, Building 6820 40789 Monheim am

More information

Development and Validation for Simultaneous Estimation of Sitagliptin and Metformin in Pharmaceutical Dosage Form using RP-HPLC Method

Development and Validation for Simultaneous Estimation of Sitagliptin and Metformin in Pharmaceutical Dosage Form using RP-HPLC Method International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.5, No.4, pp 1736-1744, Oct-Dec 2013 Development and Validation for Simultaneous Estimation of Sitagliptin and Metformin

More information

10 Sulfaquinoxaline H N O S O. 4-amino-N-quinoxalin-2-ylbenzenesulfonamide C 14 H 12 N 4 O 2 S MW: CAS No.:

10 Sulfaquinoxaline H N O S O. 4-amino-N-quinoxalin-2-ylbenzenesulfonamide C 14 H 12 N 4 O 2 S MW: CAS No.: 10 Sulfaquinoxaline N N H N O S O NH 2 4-amino-N-quinoxalin-2-ylbenzenesulfonamide C 14 H 12 N 4 O 2 S MW: 300.33 CAS No.: 59-40-5 Outline of sulfaquinoxaline Sulfaquinoxaline is light yellow to brownish

More information

Should you have any questions, please contact Heather Joyce, Ph.D., Senior Scientific Liaison ( or

Should you have any questions, please contact Heather Joyce, Ph.D., Senior Scientific Liaison ( or Divalproex Sodium Delayed-Release Capsules Type of Posting Revision Bulletin Posting Date 29 July 2016 Official Date 01 Aug 2016 Expert Committee Chemical Medicines Monographs 4 Reason for Revision Compliance

More information

ASSAY AND IMPURITY METHOD FOR DURACOR TABLETS BY HPLC

ASSAY AND IMPURITY METHOD FOR DURACOR TABLETS BY HPLC ASSAY AND IMPURITY METHOD FOR DURACOR TABLETS BY HPLC METHOD APPROVALS Norvin Pharma Inc. Author Analytical Laboratory Approver Analytical Laboratory Group Leader Approver Manager Quality Control Chemistry

More information

Diltiazem Hydrochloride Extended-Release Capsules. Type of Posting Posting Date Official Date

Diltiazem Hydrochloride Extended-Release Capsules. Type of Posting Posting Date Official Date Diltiazem Hydrochloride Extended-Release Capsules Type of Posting Posting Date Official Date Revision Bulletin 17 Nov 2017 01 Dec 2017 Expert Committee Chemical Medicines Monographs 2 Reason for Revision

More information

HYDROXYPROPYLCELLULOSE, LOW SUBSTITUTED Stage 4, Revision 1 CP: USP BRIEFING NOTE

HYDROXYPROPYLCELLULOSE, LOW SUBSTITUTED Stage 4, Revision 1 CP: USP BRIEFING NOTE 002-0901PDG.pdf HYDROXYPROPYLCELLULOSE, LOW SUBSTITUTED Stage 4, Revision 1 CP: USP BRIEFING NOTE Compared to the Stage 4, document the following changes are proposed: 1. Assay: a determination of the

More information

Simultaneous estimation of Metformin HCl and Sitagliptin in drug substance and drug products by RP-HPLC method

Simultaneous estimation of Metformin HCl and Sitagliptin in drug substance and drug products by RP-HPLC method International Journal of Chemical and Pharmaceutical Sciences 2017, Mar., Vol. 8 (1) ISSN: 0976-9390 IJCPS Simultaneous estimation of Metformin HCl and Sitagliptin in drug substance and drug products by

More information

MONOGRAPHS (NF) Pharmacopeial Forum 616 HARMONIZATION Vol. 31(2) [Mar. Apr. 2005]

MONOGRAPHS (NF) Pharmacopeial Forum 616 HARMONIZATION Vol. 31(2) [Mar. Apr. 2005] 616 HARMONIZATION Vol. 31(2) [Mar. Apr. 2005] the recorder. The substances are eluted in the following order: o-toluenesulfonamide, p-toluenesulfonamide, and caffeine. The test is not valid unless the

More information

Analytical Method for 2, 4, 5-T (Targeted to Agricultural, Animal and Fishery Products)

Analytical Method for 2, 4, 5-T (Targeted to Agricultural, Animal and Fishery Products) Analytical Method for 2, 4, 5-T (Targeted to Agricultural, Animal and Fishery Products) The target compound to be determined is 2, 4, 5-T. 1. Instrument Liquid Chromatograph-tandem mass spectrometer (LC-MS/MS)

More information

Change to read: BRIEFING

Change to read: BRIEFING BRIEFING Dibasic Calcium Phosphate Dihydrate, USP 29 page 359. The Japanese Pharmacopoeia is the coordinating pharmacopeia for the international harmonization of the compendial standards for the Dibasic

More information

Analysis of Amino Acids Derived Online Using an Agilent AdvanceBio AAA Column

Analysis of Amino Acids Derived Online Using an Agilent AdvanceBio AAA Column Application Note Pharmaceutical and Food Testing Analysis of Amino Acids Derived Online Using an Agilent AdvanceBio AAA Column Author Lu Yufei Agilent Technologies, Inc. Abstract A liquid chromatographic

More information

Available online Research Article

Available online   Research Article Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2016, 8(1):171-176 Research Article ISSN : 0975-7384 CODEN(USA) : JCPRC5 Reverse phase high performance liquid chromatography

More information

contents of the currently official monograph. Please refer to the current edition of the USP NF for official text.

contents of the currently official monograph. Please refer to the current edition of the USP NF for official text. Estradiol Transdermal System Type of Posting Notice of Intent to Revise Posting Date 28 Sep 2018 Targeted Official Date To Be Determined, Revision Bulletin Expert Committee Chemical Medicines Monographs

More information

Should you have any questions, please contact Gerald Hsu, Ph.D., Senior Scientific Liaison ( or

Should you have any questions, please contact Gerald Hsu, Ph.D., Senior Scientific Liaison ( or Estradiol Transdermal System Type of Posting Revision Bulletin Posting Date 27 Jan 2017 Official Date 01 Feb 2017 Expert Committee Chemical Medicines Monographs 5 Reason for Revision Compliance In accordance

More information

INTERIM REVISION ANNOUNCEMENT

INTERIM REVISION ANNOUNCEMENT INTERIM REVISION ANNOUNCEMENT In this section readers will find the following: The list of new USP Reference Standards that have become available The list of assays or tests that are adopted but held in

More information

Development and validation of stability indicating RP-LC method for estimation of calcium dobesilate in pharmaceutical formulations

Development and validation of stability indicating RP-LC method for estimation of calcium dobesilate in pharmaceutical formulations Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2016, 8 (11):236-242 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4

More information

ISSN (Print)

ISSN (Print) Scholars Academic Journal of Pharmacy (SAJP) Sch. Acad. J. Pharm., 2014; 3(3): 240-245 Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources) www.saspublisher.com

More information

Should you have any questions, please contact Heather Joyce, Ph.D., Senior Scientific Liaison ( or

Should you have any questions, please contact Heather Joyce, Ph.D., Senior Scientific Liaison ( or Duloxetine Delayed-Release Capsules Type of Posting Revision Bulletin Posting Date 28 July 2017 Official Date 01 Aug 2017 Expert Committee Chemical Medicines Monographs 4 Reason for Revision Compliance

More information

Available online at Scholars Research Library

Available online at  Scholars Research Library Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2015, 7 (3):157-161 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4

More information

J Pharm Sci Bioscientific Res (4): ISSN NO

J Pharm Sci Bioscientific Res (4): ISSN NO Development and Validation of Analytical Methods for Simultaneous Estimation of Pregabalin and Amitriptyline Hydrochloride in their Combined Marketed Dosage form ABSTRACT: Nikhilkumar Patel, Gurjit Kaur,

More information

Development, Estimation and Validation of Lisinopril in Bulk and its Pharmaceutical Formulation by HPLC Method

Development, Estimation and Validation of Lisinopril in Bulk and its Pharmaceutical Formulation by HPLC Method ISSN: 0973-4945; CODEN ECJAO E- Chemistry http://www.e-journals.net 2012, 9(1), 340-344 Development, Estimation and Validation of Lisinopril in Bulk and its Pharmaceutical Formulation by PLC Method V.

More information

Compliance. Minor editorial changes have been made to update the monograph to the current USP style.

Compliance. Minor editorial changes have been made to update the monograph to the current USP style. Nifedipine Extended-Release Tablets Type of Posting Revision Bulletin Posting Date 28 Jul 2017 Official Date 01 Aug 2017 Expert Committee Chemical Medicines Monographs 2 Reason for Revision Compliance

More information

CHAPTER 8 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) ANALYSIS OF PHYTOCHEMICAL CONSTITUENTS OF M. ROXBURGHIANUS AND P. FRATERNUS PLANT EXTRACTS

CHAPTER 8 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) ANALYSIS OF PHYTOCHEMICAL CONSTITUENTS OF M. ROXBURGHIANUS AND P. FRATERNUS PLANT EXTRACTS CHAPTER 8 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) ANALYSIS OF PHYTOCHEMICAL CONSTITUENTS OF M. ROXBURGHIANUS AND P. FRATERNUS PLANT EXTRACTS CHAPTER 8: HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)

More information

SIMULTANEOUS ESTIMATION OF VALSARTAN AND HYDROCHLOROTHIAZIDE IN TABLETS BY RP-HPLC METHOD

SIMULTANEOUS ESTIMATION OF VALSARTAN AND HYDROCHLOROTHIAZIDE IN TABLETS BY RP-HPLC METHOD 170 Original Article SIMULTANEOUS ESTIMATION OF VALSARTAN AND HYDROCHLOROTHIAZIDE IN TABLETS BY RP-HPLC METHOD *Lakshmana Rao A, 1 Bhaskara Raju V *V.V. Institute of Pharmaceutical Sciences, Gudlavalleru,

More information

SUMMARY, CONCLUSION & RECOMMENDATIONS

SUMMARY, CONCLUSION & RECOMMENDATIONS 196 Chapter-5 SUMMARY, CONCLUSION & RECOMMENDATIONS 197 CHAPTER 5 5.1 Summary, Conclusion and Recommendations Summary and Conclusion are drawn based on the work carried out by the author on development

More information

E17 ETHYLCELLULOSE. Revision 3 Stage 4

E17 ETHYLCELLULOSE. Revision 3 Stage 4 00-205PDG.pdf 2 E7 ETHYLCELLULOSE Revision 3 Stage 4 3 4 5 6 7 8 9 0 2 3 4 5 6 7 8 9 20 2 22 23 24 25 26 27 28 29 30 3 32 33 34 35 36 37 DEFINITION Ethylcellulose is a partly O-ethylated cellulose. It

More information

MONOGRAPHS (USP) Saccharin Sodium

MONOGRAPHS (USP) Saccharin Sodium Vol. 31(4) [July Aug. 2005] HARMONIZATION 1225 MONOGRAPHS (USP) BRIEFING Saccharin Sodium, USP 28 page 1745 and page 612 of PF 31(2) [Mar. Apr. 2005]. The United States Pharmacopeia is the coordinating

More information

CHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW

CHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW 132 CHAPTER 6 DEVELOPMENT AND VALIDATION OF A STABILITY-INDICATING RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION OF PARACETAMOL, TRAMADOL HYDROCHLORIDE AND DOMPERIDONE IN A COMBINED DOSAGE FORM 6.1 INTRODUCTION

More information

Pelagia Research Library

Pelagia Research Library Available online at www.pelagiaresearchlibrary.com Der Pharmacia Sinica, 2015, 6(1):6-10 ISSN: 0976-8688 CODEN (USA): PSHIBD Validated RP-HPLC method for simultaneous estimation of metformin hydrochloride

More information

Comparison of conventional HPLC with UPLC method for determination of albuterol sulfate and it s impurities in pharmaceutical formulation

Comparison of conventional HPLC with UPLC method for determination of albuterol sulfate and it s impurities in pharmaceutical formulation Oriental Journal of Chemistry Vol. 24(2), 537-544 (2008) Comparison of conventional HPLC with UPLC method for determination of albuterol sulfate and it s impurities in pharmaceutical formulation P.N. DALVI,

More information

Ergovaline. [Methods listed in the Feed Analysis Standards] 1 Liquid chromatography Note 1, 2 [Feed Analysis Standards, Chapter 5, Section 2

Ergovaline. [Methods listed in the Feed Analysis Standards] 1 Liquid chromatography Note 1, 2 [Feed Analysis Standards, Chapter 5, Section 2 Ergovaline C 29 35 5 5 MW: 533.619 CAS o.: 2873-38-3 [Summary of ergovaline] Ergovaline is a kind of ergot alkaloids produced by endophytes eotyphodium coenophialum and eotyphodium lolli, symbionts of

More information

REVERSE PHASE HPLC METHOD FOR THE ANALYSIS OF ALFUZOSIN HYDROCHLORIDE IN PHARMACEUTICAL DOSAGE FORMS

REVERSE PHASE HPLC METHOD FOR THE ANALYSIS OF ALFUZOSIN HYDROCHLORIDE IN PHARMACEUTICAL DOSAGE FORMS Int. J. Chem. Sci.: 6(1), 2008, 399-404 REVERSE PHASE HPLC METHOD FOR THE ANALYSIS OF ALFUZOSIN HYDROCHLORIDE IN PHARMACEUTICAL DOSAGE FORMS S. APPALA RAJU, ARVIND B. KARADI and SHOBHA MANJUNATH HKES s

More information

HEPARIN SODIUM. Heparinum natricum

HEPARIN SODIUM. Heparinum natricum Pharmeuropa 25.1 1 Reference: PA/PH/Exp. 6/T (12) 37 ANP NOTE ON THE MONOGRAPH Definition. It is proposed to restrict the scope to heparin material of porcine origin since some of the latest requirements

More information

Hyderabad, India. Department of Pharmaceutical Chemistry, Glocal University, Saharanpur, India.

Hyderabad, India. Department of Pharmaceutical Chemistry, Glocal University, Saharanpur, India. International Journal On Engineering Technology and Sciences IJETS RP-HPLC Method development and validation for the Simultaneous Estimation of Metformin and Empagliflozine in Tablet Dosage Form Shaik

More information

A simple validated RP-HPLC method for quantification of sumatriptan succinate in bulk and pharmaceutical dosage form

A simple validated RP-HPLC method for quantification of sumatriptan succinate in bulk and pharmaceutical dosage form IJPAR Vol.4 Issue 1 Jan-Mar-2015 Journal Home page: ISSN: 2320-2831 Research article Open Access A simple validated RP-HPLC method for quantification of sumatriptan succinate in bulk and pharmaceutical

More information

Relative Measurement of Zeaxanthin Stereoisomers by Chiral HPLC

Relative Measurement of Zeaxanthin Stereoisomers by Chiral HPLC Relative Measurement of Zeaxanthin Stereoisomers by Chiral HPLC Principle To measure the relative percentages of the (3R,3 R), (3R,3 S) and (3S,3 S) stereoisomers of zeaxanthin in dietary ingredient and

More information

Minor editorial changes have been made to update the monograph to the current USP style.

Minor editorial changes have been made to update the monograph to the current USP style. Nifedipine Extended-Release Tablets Type of Posting Revision Bulletin Posting Date 29 Sep 2017 Official Date 01 Oct 2017 Expert Committee Chemical Medicines Monographs 2 Reason for Revision Compliance

More information

A HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC ASSAY FOR LERCANIDIPINE HYDROCHLORIDE

A HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC ASSAY FOR LERCANIDIPINE HYDROCHLORIDE Int. J. Chem. Sci.: 6(1), 2008, 441-446 A HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC ASSAY FOR LERCANIDIPINE HYDROCHLORIDE S. APPALA RAJU, ARVIND B. KARADI and SHOBHA MANJUNATH HKES s College of Pharmacy,

More information

Pelagia Research Library

Pelagia Research Library Available online at www.pelagiaresearchlibrary.com Der Pharmacia Sinica, 2014, 5(5):91-98 ISSN: 0976-8688 CODEN (USA): PSHIBD A novel RP-HPLC method development and validation of Perindopril Erbumine in

More information

Sanjog Ramdharane 1, Dr. Vinay Gaitonde 2

Sanjog Ramdharane 1, Dr. Vinay Gaitonde 2 JPSBR: Volume 5, Issue 2: 2015 (151-155) ISS. 2271-3681 A ew Gradient RP- HPLC Method for Quantitative Analysis of : (3-luoro-4- Morpholin-4-yl-Phenyl)-Carbamic Acid Methyl Ester and its Related Substances

More information

CHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW

CHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW 51 CHAPTER 2 SIMULTANEOUS ESTIMATION OF PIOGLITAZONE, GLIMEPIRIDE AND GLIMEPIRIDE IMPURITIES IN COMBINATION DRUG PRODUCT BY A VALIDATED STABILITY-INDICATING RP-HPLC METHOD 2.1 INTRODUCTION OF DOSAGE FORM

More information

Development and Validation of a Simultaneous HPLC Method for Quantification of Amlodipine Besylate and Metoprolol Tartrate in Tablets

Development and Validation of a Simultaneous HPLC Method for Quantification of Amlodipine Besylate and Metoprolol Tartrate in Tablets Journal of PharmaSciTech 0; ():- Research Article Development and Validation of a Simultaneous HPLC Method for Quantification of Amlodipine Besylate and Metoprolol Tartrate in Tablets * Sayyed Hussain,

More information

LAVENDER FOR HOMOEOPATHIC PREPARATIONS LAVANDULA VERA FOR HOMOEOPATHIC PREPARATIONS

LAVENDER FOR HOMOEOPATHIC PREPARATIONS LAVANDULA VERA FOR HOMOEOPATHIC PREPARATIONS LAVENDER FOR HOMOEOPATHIC PREPARATIONS LAVANDULA VERA FOR HOMOEOPATHIC PREPARATIONS Lavandula angustifolia ad praeparationes homoeopathicas DEFINITION Fresh, blooming, flower-heads of Lavandula angustifolia

More information

ISSN: ; CODEN ECJHAO E-Journal of Chemistry 2011, 8(3),

ISSN: ; CODEN ECJHAO E-Journal of Chemistry  2011, 8(3), ISSN: 0973-4945; CODEN ECJHAO E- Chemistry http://www.e-journals.net 2011, 8(3), 1275-1279 Simultaneous Determination of Paracetamol, Phenylephrine Hydrochloride, Oxolamine Citrate and Chlorpheniramine

More information

RP-HPLC Analysis of Temozolomide in Pharmaceutical Dosage Forms

RP-HPLC Analysis of Temozolomide in Pharmaceutical Dosage Forms Asian Journal of Chemistry Vol. 22, No. 7 (2010), 5067-5071 RP-HPLC Analysis of Temozolomide in Pharmaceutical Dosage Forms A. LAKSHMANA RAO*, G. TARAKA RAMESH and J.V.L.N.S. RAO Department of Pharmaceutical

More information

Isocratic Reversed Phase Liquid Chromatographic Method Validation for the Determination of Cilostazol in Pure and Formulations

Isocratic Reversed Phase Liquid Chromatographic Method Validation for the Determination of Cilostazol in Pure and Formulations Human Journals Research Article October 2015 Vol.:4, Issue:3 All rights are reserved by Rambabu K et al. Isocratic Reversed Phase Liquid Chromatographic Method Validation for the Determination of Cilostazol

More information

International Journal of Pharma and Bio Sciences DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE ESTIMATION OF STRONTIUM RANELATE IN SACHET

International Journal of Pharma and Bio Sciences DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE ESTIMATION OF STRONTIUM RANELATE IN SACHET International Journal of Pharma and Bio Sciences RESEARCH ARTICLE ANALYTICAL CHEMISTRY DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE ESTIMATION OF STRONTIUM RANELATE IN SACHET K.MYTHILI *, S.GAYATRI,

More information

A New Stability-Indicating and Validated RP-HPLC Method for the Estimation of Liraglutide in Bulk and Pharmaceutical Dosage Forms

A New Stability-Indicating and Validated RP-HPLC Method for the Estimation of Liraglutide in Bulk and Pharmaceutical Dosage Forms OPEN ACCESS Eurasian Journal of Analytical Chemistry ISSN: 1306-3057 2017 12(2):31-44 DOI 10.12973/ejac.2017.00152a A New Stability-Indicating and Validated RP-HPLC Method for the Estimation of Liraglutide

More information

1 out of 8. Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 86th Meeting 2018 ERYTHROSINE

1 out of 8. Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 86th Meeting 2018 ERYTHROSINE 1 out of 8 Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 86th Meeting 2018 ERYTHROSINE This monograph was also published in: Compendium of Food

More information

IDENTIFICATION AND CONTROLOFRESIDUALSOLVENTS Identification and control of residual solvents EUROPEAN PHARMACOPOEIA 6.

IDENTIFICATION AND CONTROLOFRESIDUALSOLVENTS Identification and control of residual solvents EUROPEAN PHARMACOPOEIA 6. EUROPEAN PHARMACOPOEIA 6.0 2.4.24. Identification and control of residual solvents paper and wash each filter with 3 quantities, each of 15 ml, of methylenechlorider.placethecombinedfiltrateand washings

More information